20 Dec, EOD - Indian

SENSEX 78041.59 (-1.49)

Nifty 50 23587.5 (-1.52)

Nifty Bank 50759.2 (-1.58)

Nifty IT 43771.05 (-2.63)

Nifty Midcap 100 56906.75 (-2.82)

Nifty Next 50 68702.65 (-2.72)

Nifty Pharma 22501.85 (-0.86)

Nifty Smallcap 100 18714.3 (-2.19)

20 Dec, EOD - Global

NIKKEI 225 38701.9 (-0.29)

HANG SENG 19720.7 (-0.16)

S&P 6008.5 (1.05)

Login/Signup

You are Here : Home > Research

27-Jul-2024

Cipla

OP increased 14.85%

'For quarter ending June 2024, consolidated Net sales (including other operating income) of Cipla has increased 5.77% to Rs 6693.94 crore compared to quarter ended June 2023.  Sales of Phamaceuticals segment has gone up 5.99% to Rs 6,389.30 crore (accounting for 94.75% of total sales).  Sales of New Ventures segment has gone down 0.13% to Rs 353.98 crore (accounting for 5.25% of total sales).  Inter-segment sales came down from Rs 54.04 crore to Rs 49.34 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 17.13% to Rs 1,629.31 crore.  PBIT of Phamaceuticals segment rose 18.01% to Rs 1,630.64 crore (accounting for 100.08% of total PBIT).  PBIT of New Ventures reported loss of Rs 1.33 crore compared to profit of Rs 9.19 crore.  

PBIT margin of Phamaceuticals segment rose from 22.92% to 25.52%.  PBIT margin of New Ventures segment fell from 2.59% to 0.38%. &nbs...



Pleaselogin & subscribe to view the full report.

More Reports
More Reports View Company Information

  • Results-Analysis   (30-Oct-2024)

    Cipla

    NP up 15.18%

  • Results-Analysis   (27-Jul-2024)

    Cipla

    OP increased 14.85%

  • Results-Analysis   (13-May-2024)

    Cipla

    OP up 12.11%

  • Results-Analysis   (23-Jan-2024)

    Cipla

    NP up 31.83%